COMMUNIQUÉS West-GlobeNewswire

RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
22/07/2026
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and [...]
Ipsen finalise l'acquisition de Memo Therapeutics AG, ajoutant un actif premier de sa classe au portefeuille de maladies rares d'Ipsen
22/07/2026
PARIS, FRANCE, 22 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd'hui avoir finalisé l'acquisition de Memo Therapeutics AG - une société de biotechnologie en phase avancée de développement - portant [...]
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
22/07/2026
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 Halle (Saale) / Munich, Germany, July 22 , 2026 - Vivoryon [...]
ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
22/07/2026
Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio's leadership team as it prepares to advance RBP-01 into the clinic RBP-01 targets primary uveal melanoma, the most [...]
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07/2026
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
22/07/2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
GlycoReset Supplement Facts Released: Consumer Safety Report Details New Analysis About Glyco Reset Ingredients & Side Effects Risk
22/07/2026
Berberine, Ceylon Cinnamon, Gymnema Sylvestre, Chromium Picolinate and Four More Compounds in the Glyco Reset Drops Formula Wilmington, DE, July 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
22/07/2026
-Reverse stock split to support continued compliance with NYSE American continued listing standards- TUCSON, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company" or "Picard [...]
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
22/07/2026
SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
21/07/2026
Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell depletion, as evidenced by [...]
Flyte Partners with Blade to Expand Vision Jet Distribution
21/07/2026
Flyte's Vision Jet Fleet to Be Featured on Blade Platform, Expanding Distribution across One of the Industry's Leading Air Mobility Networks Strategic Partnership Expected to Increase Aircraft Utilization, Customer [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/07/2026
CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
21/07/2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Acquisition of Own Shares
21/07/2026
Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
21/07/2026
WARSAW, Ind., July 21, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026
21/07/2026
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today [...]
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
21/07/2026
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]

Pages